Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03743064
Registration number
NCT03743064
Ethics application status
Date submitted
14/11/2018
Date registered
15/11/2018
Date last updated
6/04/2023
Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Query!
Scientific title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Query!
Secondary ID [1]
0
0
2018-002927-40
Query!
Secondary ID [2]
0
0
ANAM-17-21
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cachexia; Cancer
0
0
Query!
Non Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Mental Health
0
0
0
0
Query!
Eating disorders
Query!
Diet and Nutrition
0
0
0
0
Query!
Other diet and nutrition disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - anamorelin HCl
Treatment: Drugs - Placebo Oral Tablet
Experimental: 100 mg anamorelin HCl - 100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
Placebo Comparator: Placebo - Placebo oral tablet (administered as matching placebo tablets in the fasted condition)
Treatment: Drugs: anamorelin HCl
100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
Treatment: Drugs: Placebo Oral Tablet
Placebo (administered as matching placebo tablets in the fasted condition)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
body weight
Query!
Assessment method [1]
0
0
Mean change in body weight
Query!
Timepoint [1]
0
0
From baseline until week 12
Query!
Primary outcome [2]
0
0
5 item Anorexia Symptom Subscale
Query!
Assessment method [2]
0
0
Mean change in 5-item Anorexia Symptom Subscale
Query!
Timepoint [2]
0
0
From baseline until week 12
Query!
Secondary outcome [1]
0
0
body weight
Query!
Assessment method [1]
0
0
Duration of treatment benefit in weight (=0).
Query!
Timepoint [1]
0
0
From baseline until week 12
Query!
Secondary outcome [2]
0
0
body weight
Query!
Assessment method [2]
0
0
Duration of treatment benefit in weight (= to a predefined threshold).
Query!
Timepoint [2]
0
0
From baseline until week 12
Query!
Secondary outcome [3]
0
0
5 item Anorexia Symptom Subscale
Query!
Assessment method [3]
0
0
Duration of treatment benefit in anorexia symptoms (=0), as measured by the 5-item Anorexia Symptom Subscale.
Query!
Timepoint [3]
0
0
From baseline until week 12
Query!
Secondary outcome [4]
0
0
5 item Anorexia Symptom Subscale
Query!
Assessment method [4]
0
0
Duration of treatment benefit in 5-item Anorexia Symptom Subscale (= to a predefined threshold).
Query!
Timepoint [4]
0
0
From baseline until week 12
Query!
Secondary outcome [5]
0
0
FAACT 12-item A/CS domain
Query!
Assessment method [5]
0
0
Mean change in FAACT 12-item A/CS domain.
Query!
Timepoint [5]
0
0
From baseline until week 12
Query!
Secondary outcome [6]
0
0
FACIT-F
Query!
Assessment method [6]
0
0
Mean change in FACIT-F.
Query!
Timepoint [6]
0
0
From baseline until week 12
Query!
Secondary outcome [7]
0
0
FAACT total score
Query!
Assessment method [7]
0
0
Mean change in FAACT total score.
Query!
Timepoint [7]
0
0
From baseline until week 12
Query!
Eligibility
Key inclusion criteria
1. Signed written informed consent
2. Female or male =18 years of age
3. Documented histologic or cytologic diagnosis of American Joint Committee on Cancer
(AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease
4. Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior
to screening
5. Ongoing problems with appetite/eating associated with the underlying cancer, as
determined by having score of = 17 points on the 5-item Anorexia Symptom Scale and =
37 points on the 12-item FAACT A/CS
6. Patient receiving or not receiving systemic anti-cancer treatment at the time of
screening are eligible to participate. Systemic anti-cancer treatment includes first,
second, third treatment line with chemotherapy/radiation therapy, immunotherapy or
targeted therapy.
Patient not receiving systemic anti-cancer treatment is eligible if:
1. Not planning to receive anti-cancer treatment and/or at least 14 days must be
elapsed from the completion of prior treatment at the day of screening, in case
underwent previous cycle OR
2. Planning to receive anti-cancer treatment within 14 days from randomization
and/or at least 14 days must be elapsed from the completion of prior treatment at
the day of screening, in case underwent previous cycle OR
3. Patient on palliative care treatment
7. ECOG performance status 0,1 or 2 at screening
8. AST (SGOT) and ALT (SGPT) = 3 x ULN or if hepatic metastases are present = 5 x ULN
9. Adequate renal function, defined as creatinine =2 ULN, or calculated creatinine
clearance >30 ml/minute
10. Female patient shall be: a) of non-childbearing potential or b) of childbearing
potential using reliable contraceptive measures and having a negative urine pregnancy
test within 24 hours prior to first dose of investigational product.
Notes:
1. Female patient of non-childbearing potential are defined as being in
post-menopausal state since at least 1 year; or having documented surgical
sterilization or hysterectomy at least 3 months before study participation.
2. Reliable contraceptive measures include implants, injectables, combined oral
contraceptives, intrauterine devices, vasectomized partner or complete (long
term) sexual abstinence.
11. The patient must be willing and able to comply with the protocol tests and procedures
All inclusion criteria will be checked at screening visit (Visit 1).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)
2. Woman who is pregnant or breast-feeding
3. Reversible causes of reduced food intake, as determined by the Investigator. These
causes may include but are not limited to:
1. NCI CTCAE Grade 3 or 4 oral mucositis,
2. NCI CTCAE Grade 3 or 4 GI disorders [nausea, vomiting, diarrhea, and
constipation],
3. mechanical obstructions making patient unable to eat, or
4. severe depression
4. Patient undergoing major surgery (central venous access placement and tumor biopsies
are not considered major surgery) within 4 weeks prior to randomization. Patient must
be well recovered from acute effects of surgery prior to screening. Patient should not
have plans to undergo major surgical procedures during the treatment period
5. Patient currently taking androgenic compounds (including but not limited to
testosterone, testosterone-like agents, oxandrolone, megestrol acetate,
corticosteroids, olanzapine, mirtazapine (however, long-term use of mirtazapine for
depression for at least four weeks prior to screening is allowed), dronabinol or
marijuana (cannabis) or any other prescription medication or off-label products
intended to increase appetite or treat unintentional weight loss
6. Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring
drainage, edema or evidence of ascites
7. Patient with uncontrolled or significant cardiovascular disease, including:
1. History of myocardial infarction within the past 3 months
2. A-V block of second or third degree (may be eligible if currently have a
pacemaker)
3. Unstable angina
4. Congestive heart failure within the past 3 months, if defined as NYHA class
III-IV
5. Any history of clinically significant ventricular arrhythmias (such as
ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW)
syndrome, or torsade de pointes)
6. Uncontrolled hypertension (blood pressure >150 mm Hg systolic and >95 mm Hg
diastolic)
7. Heart rate < 50 beats per minute on pre-entry electrocardiogram and patient is
symptomatic
8. Patient on drugs that may prolong the PR or QRS interval durations, such as any of the
antiarrhythmic medications Class I (Fast sodium (Na) channel blockers)
9. Patient unable to readily swallow oral tablets
10. Patient with severe gastrointestinal disease (including esophagitis, gastritis,
malabsorption)
11. Patient with history of gastrectomy
12. Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus
13. Patient with cachexia caused by other reasons, as determined by the investigator such
as:
1. Severe COPD requiring use of home O2,
2. New York Heart Association (NYHA) class III-IV heart failure
3. AIDS
4. Uncontrolled thyroid disease
14. Patient receiving strong CYP3A4 inhibitors within 14 days of randomization
15. Patient currently receiving tube feedings or parenteral nutrition (either total or
partial).
16. Current excessive alcohol or illicit drug use
17. Any condition, including the presence of laboratory abnormalities, which in the
Investigator's opinion, places the subject at unacceptable risk if he/she were to
participate in the study or confounds the ability to interpret data from the study
18. Enrollment in a previous study with anamorelin HCl
19. Patient actively receiving a concurrent investigational agent, or having received an
investigational agent within 28 days of Day 1 All exclusion criteria will be checked
at screening visit (Visit 1).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
18/12/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/12/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
318
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
Calvary Central Districts Hospital - Elizabeth Vale
Query!
Recruitment hospital [2]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [3]
0
0
St Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment hospital [4]
0
0
Barwon Health, The McKellar Centre - North Geelong
Query!
Recruitment hospital [5]
0
0
The Royal Melbourne Hospital - Parkville
Query!
Recruitment hospital [6]
0
0
Gold Coast University Hospital - Southport
Query!
Recruitment postcode(s) [1]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [2]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [4]
0
0
3215 - North Geelong
Query!
Recruitment postcode(s) [5]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [6]
0
0
4215 - Southport
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Hampshire
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Jersey
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Brussels
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Charleroi
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Edegem
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Roeselare
Query!
Country [19]
0
0
Croatia
Query!
State/province [19]
0
0
Pula
Query!
Country [20]
0
0
Croatia
Query!
State/province [20]
0
0
Split
Query!
Country [21]
0
0
Croatia
Query!
State/province [21]
0
0
Zagreb
Query!
Country [22]
0
0
Poland
Query!
State/province [22]
0
0
Grudziadz
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Katowice
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Poznan
Query!
Country [25]
0
0
Poland
Query!
State/province [25]
0
0
Prabuty
Query!
Country [26]
0
0
Poland
Query!
State/province [26]
0
0
Warsaw
Query!
Country [27]
0
0
Poland
Query!
State/province [27]
0
0
Wieliszew
Query!
Country [28]
0
0
Poland
Query!
State/province [28]
0
0
Lódz
Query!
Country [29]
0
0
Romania
Query!
State/province [29]
0
0
Cluj County
Query!
Country [30]
0
0
Romania
Query!
State/province [30]
0
0
Dolj County
Query!
Country [31]
0
0
Romania
Query!
State/province [31]
0
0
Maramures
Query!
Country [32]
0
0
Romania
Query!
State/province [32]
0
0
Murers
Query!
Country [33]
0
0
Romania
Query!
State/province [33]
0
0
Suceava County
Query!
Country [34]
0
0
Romania
Query!
State/province [34]
0
0
Timis
Query!
Country [35]
0
0
Romania
Query!
State/province [35]
0
0
Bucharest
Query!
Country [36]
0
0
Russian Federation
Query!
State/province [36]
0
0
Kazan
Query!
Country [37]
0
0
Russian Federation
Query!
State/province [37]
0
0
Pyatigorsk
Query!
Country [38]
0
0
Russian Federation
Query!
State/province [38]
0
0
Saint Petersburg
Query!
Country [39]
0
0
Russian Federation
Query!
State/province [39]
0
0
Samara
Query!
Country [40]
0
0
Russian Federation
Query!
State/province [40]
0
0
Saransk
Query!
Country [41]
0
0
Russian Federation
Query!
State/province [41]
0
0
Sochi
Query!
Country [42]
0
0
Russian Federation
Query!
State/province [42]
0
0
St. Petersburg
Query!
Country [43]
0
0
Russian Federation
Query!
State/province [43]
0
0
Volgograd
Query!
Country [44]
0
0
Ukraine
Query!
State/province [44]
0
0
Kharkiev Region
Query!
Country [45]
0
0
Ukraine
Query!
State/province [45]
0
0
Kharkiev
Query!
Country [46]
0
0
Ukraine
Query!
State/province [46]
0
0
Kyviv
Query!
Country [47]
0
0
Ukraine
Query!
State/province [47]
0
0
Poltava Region
Query!
Country [48]
0
0
Ukraine
Query!
State/province [48]
0
0
Dnipro
Query!
Country [49]
0
0
Ukraine
Query!
State/province [49]
0
0
Kyiv
Query!
Country [50]
0
0
Ukraine
Query!
State/province [50]
0
0
Ternopil'
Query!
Country [51]
0
0
Ukraine
Query!
State/province [51]
0
0
Zaporizhzhya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Helsinn Healthcare SA
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate
the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC
with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once
daily (QD) for a total of 24 weeks. Patients will be instructed to take the study drug at
least 1 hour before their first meal of the day
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03743064
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03743064
Download to PDF